Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and characterization of a novel class of cyclic peptidic compounds inhibiting the subunit interaction of the protein kinase CK2α<sub>2</sub>β<sub>2</sub> holoenzyme.

RSC chemical biology·2026
Same author

Pannexin1-dependent and -independent protection by novel peptidomimetics against cardiac ischemia/reperfusion injury.

Scientific reports·2026
Same author

Structure-Property Relationship Analysis of α-Keto Ester Prodrugs of Monomethyl Fumarate as NRF2 Activators.

ACS chemical neuroscience·2026
Same author

Reaching Increased Hydrogel Stability <i>In Vivo</i> through β-Hairpin Peptide-Based Hydrogels.

Biomacromolecules·2026
Same author

Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Nano-G<sub>s</sub> Protein Peptidomimetics: Rational Design of Gα C-Terminus-Derived Peptides Mimicking Key Components of G<sub>s</sub>-β<sub>2</sub>AR Interactions.

Angewandte Chemie (International ed. in English)·2026

Related Experiment Video

Updated: Jul 1, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Multiple ligands in opioid research.

Steven Ballet1, Markus Pietsch, Andrew D Abell

  • 1School of Chemistry and Physics, University of Adelaide, North Terrace, Adelaide SA 5005, Australia. steven.ballet@adelaide.edu.au

Protein and Peptide Letters
|September 11, 2008
PubMed
Summary

Researchers are developing bivalent opioid ligands to enhance pain relief. These novel compounds aim to improve drug selectivity and reduce side effects like tolerance and dependence.

More Related Videos

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Jul 1, 2026

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
07:48

Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis

Published on: July 3, 2015

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Neuroscience

Background:

  • Opioid receptors (mu, delta, kappa) interact, prompting the development of bivalent ligands.
  • Bivalent ligands aim to improve selectivity and affinity for opioid receptor subtypes.
  • Minimizing opioid-induced side effects (e.g., physical dependence, tolerance) is a key goal.

Purpose of the Study:

  • To provide an overview of efforts in developing bivalent opioid ligands.
  • To explore strategies for enhancing the pharmacological profile of analgesics.
  • To investigate novel ligand designs for pain-related research.

Main Methods:

  • Design and synthesis of dimer analogues of monovalent opioid structures.
  • Evaluation of endogenous and exogenous peptide dimer analogues.
  • Preparation of mixed peptidic-non-peptidic and dual non-peptidic bivalent ligands.
  • Construction of chimeric structures combining opioid and non-opioid pharmacophores.

Main Results:

  • Various bivalent opioid ligand designs have been synthesized and evaluated.
  • Different classes of bivalent ligands include peptide dimers, mixed dimers, and dual dimers.
  • Chimeric structures incorporating non-opioid pharmacophores have also been prepared.

Conclusions:

  • Bivalent opioid ligand development is a promising strategy for improved analgesia.
  • These ligands offer potential for enhanced selectivity and reduced side effects.
  • Further research into bivalent opioid ligands is crucial for advancing pain management.